Three patent claims, one present in each of three US patents
held by the Finch Therapeutics Group Inc. (Finch), have been found
to have been infringed by Ferring Pharmaceuticals Inc.'s
(Ferring) activities in the US and relating to their enema IMT
product, REBYOTA®.
This decision, laid down by a jury in a federal trial in
Delaware on 9 August 2024, concluded with an award of $25 million
in damages and future royalties to be paid to Finch.
Commercial-IP strategies are almost never won or lost in a
single court skirmish, but what might this practically mean for
Ferring, for Finch, and indeed the wider community of microbiome
therapeutic developers?
These proceedings were first brought by Ferring in December,
2021to request a judgement of invalidity or non-infringement for
seven patents held by Finch. Presumably, this was part of a
strategy to "clear the way" in the US for the launch of
their REBYOTA® product, a product that was approved for sale in
the US by the